$4.37
+0.02
(+0.46%)▲
2.06%
Downside
Day's Volatility :5.1%
Upside
3.1%
42.77%
Downside
52 Weeks Volatility :52.72%
Upside
17.39%
Period | Dogwood Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -7.51% | 0.0% |
6 Months | -58.5% | 0.0% |
1 Year | -78.43% | 0.0% |
3 Years | -97.14% | -25.1% |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Sell
Neutral
Buy
Dogwood Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Dogwood Therapeutics Inc | 9.87% | -58.5% | -78.43% | -97.14% | -98.95% |
Regeneron Pharmaceuticals, Inc. | -18.91% | -10.03% | 3.03% | 32.07% | 171.22% |
Biontech Se | -6.32% | 20.86% | 20.53% | -61.49% | 487.66% |
Alnylam Pharmaceuticals, Inc. | 0.87% | 82.23% | 69.57% | 63.38% | 198.57% |
Vertex Pharmaceuticals Incorporated | 1.94% | 17.73% | 25.11% | 159.71% | 136.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Dogwood Therapeutics Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Regeneron Pharmaceuticals, Inc. | 20.75 | 20.75 | 1.18 | 44.77 | 0.17 | 0.08 | NA | 242.47 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Dogwood Therapeutics Inc | NA | NA | -98.95% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $101.7B | 171.22% | 20.75 | 32.04% |
Biontech Se | Buy | $27.1B | 487.66% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 198.57% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 136.25% | 32.84 | -4.74% |
Insights on Dogwood Therapeutics Inc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.6% return, outperforming this stock by 148.0%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 63.4% return, outperforming this stock by 160.5%
Organization | Dogwood Therapeutics Inc |
Industry | Miscellaneous |
Victoryshares International
$4.37
+0.46%
Clearbridge Focus Value Esg Etf
$4.37
+0.46%
Cabana Target Drawdwn 10 Etf
$4.37
+0.46%
Spdr Nyse Technology Etf
$4.37
+0.46%
Cp High Yield Trend Etf
$4.37
+0.46%
Gain Therapeutics Inc
$4.37
+0.46%
Spdr S&p Emerging Markets Ex-china Etf
$4.37
+0.46%
Proshares Bitcoin Strategy Etf
$4.37
+0.46%
Xtrackers Msci Kokusai Eqty
$4.37
+0.46%